Treatment update on spondyloarthropathy

Current Opinion in Rheumatology

Volumn 17, Issue 3, 2005, Pages 247-254

  Anandarajah, Allen ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor ; Methotrexate; Physiotherapy; Psoriatic arthritis; Reactive arthritis; Spondyloarthropathy; Therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANGIOGENIC FACTOR; ANTIRHEUMATIC AGENT; AZATHIOPRINE; AZITHROMYCIN; CYCLOSPORIN; ETANERCEPT; ETRETINATE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; B LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME;

ANGIOGENESIS INDUCING AGENTS; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; HUMANS; PHYSICAL THERAPY MODALITIES; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18244408791     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000159926.42761.dd     Document Type: Review

References (60)

1. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61 (Suppl 3);iii40-iii50.
2. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatol 2003; 42:1460-1468.
3. Chorus AM, Miedema HS, Boonen A, et al. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003; 63:1178-1184.
4. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002; 136:896-907.
5. Madden DR, Gorga JC, Strominger JL, et al. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353:321-325.
6. Brophy S, Hickey S, Menon A, et al. Concordance of disease severity among family members with ankylosing spondylitis?. J Rheumatol 2004; 31:1775-1778.
7. van der Heijde D. New directions in classification and outcome assessment in ankylosing spondylitis. Current Rheum Rep 2004; 6:98-101.
8. Dagfinrud H, Kvien TK, Hagen KB, et al. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database of Systematic Reviews, 2004. 4: p. 4.
9. Clegg DO, Reda GA, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2004-2012.
10. Chen J. and L. C., Methotrexate for ankylosing spondylitis. Cochrane Database of Systematic Reviews., 2004. 4.
11. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis. J Rheumatol 2004; 31:1568-1574.
12. Haibel H, Rudwaleit M, Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64:124-126.
13. Braun J, Brandt J, Lisling J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-1193.
14. Anderson JJ, Baron J, Van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2004; 44:1876-1886.
15. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346:1349-1356.
16. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48:1667-1675.
17. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicenter randomizes clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63:1594-1600. First European controlled trial of etanercept in AS.
18. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministratbn in patients with active ankylosing spondylitis. Rheumatol, 2004. Nov 23; [Epub ahead of print]. http://rheumatology. oupjournals. org/cgi/reprint/keh475v1 This trial demonstrated that continuous therapy with etanercept is required to control disease activity in AS.
19. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 23-week randomized, placebo-controlled trial (ASSERT). Ann Rheum Dis 2005; 52:582-591. Phase III trial of infliximab in AS. Abstract was presented at the 2004 EULAR meeting.
20. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63:665-670.
21. Landewe R, Rump B, van der Heijde D, et al. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis 2004; 63:530-534.
22. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatol 2004; 43:1158-1166. Well-designed and insightful analysis of infliximab cost-effectiveness in AS.
23. Vaz A, Barton J, Ritchlin C. Psoriatic arthritis; an update for clinicians. Int J Adv Rheumatol 2004; 2:126-134.
24. Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004; 16:350-356. Excellent review of domains and outcome measures in PsA.
25. Gladman DD, Helliwell P, Meuse PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004; 50:24-35. Comprehensive and detailed review of all of the outcome measures that have been applied in PsA clinical trials.
26. McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63:162-169.
27. Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 2004; 16:366-370.
28. Jones G, Brooks P, Crotty M, et al. A systematic review of therapies for psoriatic arthritis. Cochrane Database of Systematic Reviews, 2004; 4:4.
29. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining inflammation and proinflammatory cytokine expression in psoriatic arthritis patients treated with methotrexate. Arthritis Rheum 2004; 50:3286-3295.
30. Hirata S, Matsubara T, Saura R, et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 31:1065-1073.
31. Fraser A, van Kuijk AW, Westhavens R, et al. A randomized, double-blind, placebo-controlled, multicenter trial of combination therapy with methotrexate and cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2004; Nov 4 [Epub ahead of print].
32. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50:1939-1950. This well-designed clinical trial investigated the efficacy of leflunomide in PsA. The drug was effective, but many patients could not tolerate it, and hepatotoxicity was observed in this short-term study.
33. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-390.
34. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2002; 46(Suppl 9):S381.
35. Mease PJ, Kivitz RJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-2272. This was a phase III trial of etanercept in PsA, Etanercept was effective for the skin and joint manifestations, confirming the phase II data, and this study showed for the first time that TNF blockade can retard radiographic progression.
36. Kavanaugh A, Krueger GG, De Viam K, et al. Infliximab improves arthritis and psoriasis in patients with active polyarticular psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2004; 63(Suppl 1):402. This was the first phase III trial of infliximab in PsA. Infliximab was effective for joint and skin manifestations of PsA.
37. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769-773.
38. Smeets TJ, Kraan MC, van Loon ME, et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48:2155-2162.
39. Goedkoop A, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-center study. Arthritis Res Ther 2004; 6:R326-R334.
40. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004; 50:1636-1641.
41. Mease P, Gladman DD, Ritchlin CT, et al. Adalimumab therapy in patients with psoriatic arthritis; 24-week results of a phase III study. Arthritis Rheum 2004; 50:4097. This was the first phase III trial of adalimumab in PsA. The drug was safe and effective for the treatment of the skin and joint disease in PsA.
42. Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31:531-538.
43. Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 30:118-122.
44. Sieper J. Disease mechanisms in reactive arthritis. Curr Rheumatol Rep 2004; 6:110-116.
45. Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 41:6-14.
46. Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004; 63:1113-1119.
47. Carter J, Valeriano J, Vasey F. Doxycycline versus doxycycline plus rifampamycin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. J Rheumatol 2004; 31:1973-1980. This was the first study to show that treatment of undifferentiated SpA with a combination of antibiotics can relieve musculoskeletal signs and symptoms.
48. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004; 16:338-343.
49. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4lg-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243-1252.
50. Kremer JM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am, 2004; 30:381-391.
51. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719-727 [see comment].
52. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002; 16:755-758.
53. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059-1066.
54. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 7:485-493.
55. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
56. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 28:1544-1552.
57. Jang S, Uematsu S, Akira S, et al. IL-6 and IL-10 induction from dendritic cells in response to mycobacterium tuberculosis is predominantly dependent on TLR2-mediated recognition. J Immunol 2004; 173:3392-3397.
58. Leopold CS, Maibach HI. PVAC. Curr Opin Investig Drugs 2002; 3:1604-1607.
59. Balagon MV, Tan PL, Prestidge R, et al. Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC): results of an open-label trial. Clin Exp Dermatol 2001; 26:233-241.
60. Dalbeth N, Yeoman S, Dockerty JL, et al. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann Rheum Dis 2004; 63:718-722.